# EDGAR Filing Document

**Accession Number:** 0000846475
**File Stem:** 0001104659-25-099361
**Filing Date:** 2025-10
**Character Count:** 15364
**Document Hash:** 38228f4425c3a7c54308460721e7d4ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-099361.hdr.sgml**: 20251014

**ACCESSION NUMBER**: 0001104659-25-099361

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251007

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251014

**DATE AS OF CHANGE**: 20251014

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZYNEX INC
- **CENTRAL INDEX KEY:** 0000846475
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 870403828
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38804
- **FILM NUMBER:** 251392758

**BUSINESS ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** (800)-495-6670

**MAIL ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS INC
- **DATE OF NAME CHANGE:** 20050812

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS   INC
- **DATE OF NAME CHANGE:** 20040120

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FOX RIVER HOLDINGS  INC
- **DATE OF NAME CHANGE:** 20031126

?xml version='1.0' encoding='ASCII'? Zynex, Inc._October 7, 2025

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 7, 2025

**Zynex, Inc.**

(Exact Name of Registrant as Specified in its Charter)

&nbsp;&nbsp;&nbsp;&nbsp; Nevada&nbsp;&nbsp;&nbsp;&nbsp; 001-38804 90-0275169 <br> (State or other jurisdiction of incorporation) Commission FileNumber (I.R.S. Employer Identification number)

9655 Maroon Circle, Englewood, CO 80112

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (800) 495-6670

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

d nan

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker symbol(s) | Name of each exchange on which<br>registered |
| Common Stock, $0.001 par value per share | ZYXI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Appointment of Bret W. Wise as Director*

Mr. Wise is a retired senior executive with significant operational and financial management experience in the medical device industry. Mr. Wise served as Chair and Chief Executive Officer of Dentsply International from January 2007 through February 2016, and as Executive Chair of Dentsply Sirona from March 2016 through September 2017. From 2002 through 2006, Mr. Wise served in various positions at Dentsply International, including President, Chief Operating Officer, and Chief Financial Officer.

Prior to 2002, Mr. Wise was Chief Financial Officer of two publicly traded companies and held various positions of increasing responsibility including audit partner with KPMG, a global accounting firm. Mr. Wise has previously served on the Board of Directors of two other publicly traded companies, IMS Health Inc. and Pall Corporation, and two additional private companies. Mr. Wise currently serves as a member of the Board of Directors of Zest Dental Solutions, a private medical device company, and as a member of the Clinical Advisory Board of the Kansas City University College of Dental Medicine.

The selection of Mr. Wise to serve as a director of the Company was not pursuant to any arrangement or understanding with any other person. There are no family relationships between Mr. Wise and any director or executive officer of the Company and there are no transactions between Mr. Wise and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

For his service as a director, Mr. Wise will receive an annual cash retainer of (i) $40,000 for service on the Board of Directors, (ii) $20,000 for service as the Chair of the Audit Committee, (iii) $7,500 for service on the Compensation Committee, and (iv) $5,000 for service on the Nominating and Corporate Governance Committee, in each case payable in four equal quarterly installments, in arrears, for each three-month period following the date that the applicable annual retainer is initially payable to Mr. Wise. Each such annual retainer will be pro-rated in the event that Mr. Wise's service as a director terminates before the expiration of any three-month period for which such annual retainer was paid. Mr. Wise is also entitled to receive (i) an initial award of 20,000 shares of restricted stock and (ii) an annual award of 10,000 shares of restricted stock upon being re-elected to the Board of Directors, which awards vest quarterly in equal installments over three years beginning one quarter after the grant date, subject to Mr. Wise's continued service on the Board of Directors through each such vesting date.

Mr. Wise is expected to enter into the Company's standard form indemnification agreement in the form filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on July 2, 2025.

*Compensation of Thomas Sandgaard*

As previously announced on June 30, 2025, Thomas Sandgaard retired his position as Chief Executive Officer and has continued his role as Chair of the Board of Directors and Chair of the Technology Committee of the Board of Directors effective as of August 18, 2025. In addition to receiving the initial and annual equity awards for non-employee directors described under the heading "Director Compensation" in the Company's definitive proxy statement on Schedule 14A relating to the Company's 2025 annual meeting of stockholders (the "Proxy Statement"), filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025, which description is incorporated herein by reference, and in lieu of the annual retainer for service on the Board of Directors described thereunder, Mr. Sandgaard will receive: (i) an annual retainer of $150,000 for his service as Chair of the Board of

Directors and (ii) an annual retainer of $250,000 for his service as Chair of the Technology Committee, in each case, paid quarterly in arrears.

*Departure of Officer*

On October 8, 2025, Anna Lucsok notified the Company of her decision to resign from her position as Chief Commercial Officer of the Company, effective as of October 10, 2025.

**Item 7.01 Regulation FD Disclosure.**

On October 14, 2025, the Company issued a press release announcing the election of Mr. Wise to serve as a director. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits

---

| | |
|:---|:---|
| &nbsp;&nbsp;Exhibit<br>No. | &nbsp;&nbsp;Description |
| &nbsp;&nbsp;99.1 | &nbsp;&nbsp;[Press Release of Zynex, Inc. dated October 14, 2025.](zyxi-20251007xex99.htm) |
| &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZYNEX, INC.** | **ZYNEX, INC.** |
| Dated: October 14, 2025 | By: | /s/ Vikram Bajaj |
|  | Name:  | Vikram Bajaj |
|  | Title: | Chief Financial Officer |

---

## Ex-99

**Exhibit 99.1**

 **Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair**

ENGLEWOOD, Colo., October 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee.

"Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed commitment to integrity and compliance," said Steven Dyson, Chief Executive Officer.

Mr. Wise is a retired senior executive with significant operational and financial management experience in the medical device industry. Mr. Wise served as Chair and Chief Executive Officer of Dentsply International from January 2007 through February 2016, and as Executive Chair of Dentsply Sirona from March 2016 through September 2017. From 2002 through 2006, Mr. Wise served in various positions at Dentsply International, including President, Chief Operating Officer, and Chief Financial Officer.

Prior to 2002, Mr. Wise was Chief Financial Officer of two publicly traded companies and held various positions of increasing responsibility including audit partner with KPMG, a global accounting firm. Mr. Wise has previously served on the Board of Directors of two other publicly traded companies, IMS Health Inc. and Pall Corporation, and two additional private companies. Mr. Wise currently serves as a member of the Board of Directors of Zest Dental Solutions, a private medical device company, and as a member of the Clinical Advisory Board of the Kansas City University College of Dental Medicine.

"I am honored to take on this role as Chair of the Audit Committee at such a pivotal time for Zynex," said Mr. Wise. "I look forward to working with the rest of the Board and management team as we chart a new course for the future."

"We are pleased to welcome Bret Wise to the Board," said Thomas Sandgaard, founder and Chair of the Board. "We believe Mr. Wise's financial expertise will add significant value to Zynex as we continue our commitment to the highest standards of financial oversight and transparency."

**Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to the discussion of our plans, strategies and objectives for future operations and the anticipated benefits of the Board update discussed herein; and other similar statements.

Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and

------

assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; the outcome of the Tricare payment suspension; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, market conditions; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.

These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

**About Zynex, Inc.**

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

**Investor Relations Contact:**

Vikram Bajaj, CFO

ir@zynex.com

------